TPST2 and melanoma: In addition, mRNA expression levels of TPST2 were significantly reduced in anti-PD1-treated melanoma patients with complete response compared to patients with progressive disease or partial response [14] (Fig. S5b), and in anti-PD-L1 (atezolizumab)-treated urothelial cancer patients with partial or complete response compared to progressive or stable disease [15] (P = 0.004; Fig. S5c).